The Food and Drug Administration (FDA) says that it will not be creating rules to allow the marketing of CBD as dietary supplements or food items, leaving the massive industry without regulations despite repeated calls for administrative action from lawmakers, advocates and stakeholders.<\/p>\n
Following a \u201ccareful review\u201d of the non-intoxicating cannabinoid, FDA said it reached the conclusion that the existing regulatory pathways that are in place for other dietary supplements and food additives will not work for CBD. Instead, the agency said that wants to \u201cwork with Congress on a new way forward.\u201d<\/p>\n
In the meantime, FDA is also denying three citizen petitions that had requested rulemaking for the marketing of CBD.<\/p>\n
The announcement comes days after the agency released finalized guidance<\/a> that focuses on developing cannabis-based drugs and outlined the process and unique considerations for scientists when it comes to hemp and marijuana.<\/p>\n After careful review, the FDA has concluded that a new regulatory pathway for CBD is needed that balances individuals\u2019 desire for access to CBD products w\/ the regulatory oversight needed to manage risks. We’re prepared to work w\/ Congress on this matter. https:\/\/t.co\/cz2LpCpr9W<\/a> pic.twitter.com\/VRciiVS9nJ<\/a><\/p>\n \u2014 U.S. FDA (@US_FDA) January 26, 2023<\/a><\/p>\n<\/blockquote>\n\n FDA isn\u2019t saying that CBD shouldn\u2019t be regulated; rather, it said that certain safety concerns and data gaps make it an administrative impossibility under the current standards.<\/p>\n \u201cA new regulatory pathway would benefit consumers by providing safeguards and oversight to manage and minimize risks related to CBD products,\u201d FDA Principal Deputy Commissioner Janet Woodcock said. \u201cSome risk management tools could include clear labels, prevention of contaminants, CBD content limits, and measures, such as minimum purchase age, to mitigate the risk of ingestion by children. In addition, a new pathway could provide access and oversight for certain CBD-containing products for animals.\u201d<\/p>\n Today we are announcing that after careful review, the FDA has concluded that a new regulatory pathway for CBD is needed that balances individuals\u2019 desire for access to CBD products with the regulatory oversight needed to manage risks.<\/p>\n \u2014 Dr. Janet Woodcock (@DrWoodcockFDA) January 26, 2023<\/a><\/p>\n<\/blockquote>\n\n The agency\u2019s emphasis on working with Congress to address the issue legislatively comes as the newly seated chair of the House Oversight and Accountability Committee, Rep. James Comer (R-KY), says he is preparing to confront FDA over their failure to enact regulations<\/a> for hemp-derived products like CBD.<\/p>\n \u201cThe FDA\u2019s existing foods and dietary supplement authorities provide only limited tools for managing many of the risks associated with CBD products,\u201d Woodcock said<\/a>. \u201cUnder the law, any substance, including CBD, must meet specific safety standards to be lawfully marketed as a dietary supplement or food additive.\u201d<\/p>\n \u201cThe FDA will continue to take action against CBD and other cannabis-derived products to protect the public, in coordination with state regulatory partners, when appropriate. We will remain diligent in monitoring the marketplace, identifying products that pose risks and acting within our authorities. The FDA looks forward to working with Congress to develop a cross-agency strategy for the regulation of these products to protect the public\u2019s health and safety.\u201d<\/p>\n The FDA looks forward to working with Congress to develop a cross-agency strategy for the regulation of these products to protect the public\u2019s health and safety.<\/p>\n \u2014 Dr. Janet Woodcock (@DrWoodcockFDA) January 26, 2023<\/a><\/p>\n<\/blockquote>\n\n Relatedly, FDA denied citizen petitions for CBD rulemaking from the Council for Responsible Nutrition<\/a>, Natural Products Association<\/a> and Consumer Healthcare Products Association<\/a>.<\/p>\n This is frustrating news for advocates and stakeholders who\u2019ve been strongly pushing FDA to take some regulatory action on hemp-based products like CBD as the market continues to rapidly expand with few guardrails in place.<\/p>\n FDA has faced increased pressure from bipartisan lawmakers and industry groups to do something about the issue since hemp and its derivatives were federally legalized under the 2018 Farm Bill.<\/p>\n It did say in a notice<\/a> that industry stakeholders cold \u201cprovide input regarding this announcement\u201d either by submitting public comment or participating in engagement meetings that it will be hosting over the \u201cnext several months.\u201d<\/p>\n Top officials in the agency have previously signaled that they felt it may take work from Congress to adequately regulate CBD<\/a>.<\/p>\n \u201cIt\u2019s likely we will see FDA continue to maintain its non-enforcement approach and deference to the states, except where products have material public safety concerns,\u201d Shawn Hauser, partner at Vicente Sederberg LLP who co-chairs the firm\u2019s Hemp and Cannabinoids Department, told Marijuana Moment.<\/p>\n \u201cWoodcock is clear FDA will maintain its current enforcement approach to protect public safety in coordination with state agencies, where appropriate,\u201d she said. \u201cI expect we will continue to see more robust state regulatory programs governing finished hemp products, including limitations on THC content and synthetics.\u201d<\/p>\n Michael Bronstein, president of the American Trade Association for Cannabis & Hemp (ATACH), said in a press release that \u201cFDA\u2019s findings highlight the increased need for Congressional action as it relates to the regulatory framework of CBD products for use in food, beverage, and as dietary supplements.\u201d<\/p>\n \u201cWe will diligently work with Congress to develop and advance a pathway that protects consumers, creates certainty in the marketplace for CBD goods, and provides for sound regulation,\u201d he said.<\/p>\n An FDA cannabis task force FDA assessed concerns about whether CBD can be used safely in the long-term, and what impacts consumption might have during pregnancy. The rise in popularity of delta-8 THC products, which the Drug Enforcement Administration (DEA) says are not controlled substances, has further complicated rulemaking.<\/p>\n The FDA looks forward to working with Congress to develop a cross-agency strategy for the regulation of these products to protect the public\u2019s health and safety.<\/p>\n \u2014 Dr. Janet Woodcock (@DrWoodcockFDA) January 26, 2023<\/a><\/p>\n<\/blockquote>\n\n Reps. Morgan Griffith (R-VA) and Brett Guthrie (R-KY) sent a letter to FDA Commissioner Robert Califf in September, demanding answers over the\u00a0continued lack of regulations for CBD<\/a>\u00a0for those purposes.<\/p>\n Griffith and other bipartisan lawmakers\u00a0sent a separate, related letter to the FDA commissioner<\/a>\u00a0in August. They expressed frustration over the \u201ccompletely insufficient response\u201d the agency provided in response to their bill calling for hemp-derived CBD to be permitted and regulated as a food additive.<\/p>\n After the\u00a0CBD Product Safety and Standardization Act<\/a>\u00a0was filed in December 2021, the sponsors sought technical assistance from FDA to advise on key provisions. But four months after they sent the inquiry, FDA returned a \u201cone-page\u201d response that was \u201csimply a reformatting of a document provided to Congress over two years ago,\u201d the lawmakers said<\/p>\n At a House Appropriations subcommittee hearing in May, FDA\u2019s Califf recognized that the agency\u00a0had moved slowly with rulemaking for CBD<\/a>\u00a0in the food supply, stating that the situation \u201clooks pretty much the same in terms of where we are now\u201d as compared to when he first worked on the issue in 2016.<\/p>\n He said the FDA has taken steps to research the safety profile of cannabinoids to inform future rules, but he also punted the criticism about inaction to Congress, saying he doesn\u2019t feel that \u201cthe current authorities we have on the food side or the drug side necessarily give us what we need to have to get the right pathways forward.\u201d<\/p>\n \u201cWe\u2019re going to have to come up with something new,\u201d Califf said. \u201cI\u2019m very committed to doing that.\u201d<\/p>\n FDA also recently touted its role helping a state agency crack down on a company selling delta-8 THC gummies<\/a>\u00a0that they said are linked to \u201cserious adverse events.\u201d<\/p>\n In November, the agency\u00a0sent warning letters to five companies<\/a>\u00a0that sell foods and beverages containing CBD.<\/p>\n The agency didn\u2019t specify why it targeted those particular five companies out of the many more that market similar cannabidiol-infused consumables, but it said that they sell products \u201cthat people may confuse for traditional foods or beverages which may result in unintentional consumption or overconsumption of CBD.\u201d<\/p>\n All of this comes in the background of a major task for FDA: Conducting a scientific review into marijuana, at the direction of President Joe Biden, to aid in an assessment of its federal scheduling. FDA\u2019s recommendation won\u2019t be binding, but officials say they expect DEA to product a scheduling recommendation that\u2019s consistent with their findings about its risks and benefits.<\/p>\n North Carolina GOP Senator Refiles Medical Marijuana Legalization Bill, With Key Leader Calling It \u2018The Right Thing\u2019 To Do<\/a><\/p>\n<\/blockquote>\n\n Photo courtesy of Kimzy Nanney<\/a>.<\/em><\/p>\n The post FDA Announces It Will Not Issue Rules To Allow CBD As Dietary Supplements Or Food Items, Punting To Congress For Regulations<\/a> appeared first on Marijuana Moment<\/a>.<\/p>\n
The Food and Drug Administration (FDA) says that it will not be creating rules to allow the marketing of CBD as dietary supplements or food items, leaving the massive industry without regulations despite repeated calls for administrative action from lawmakers, advocates and stakeholders. Following a \u201ccareful review\u201d of the non-intoxicatingContinue Reading<\/a><\/span><\/p>\n","protected":false},"author":458,"featured_media":0,"comment_status":"false","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[18,81],"tags":[],"_links":{"self":[{"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/posts\/61234"}],"collection":[{"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/users\/458"}],"replies":[{"embeddable":true,"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/comments?post=61234"}],"version-history":[{"count":1,"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/posts\/61234\/revisions"}],"predecessor-version":[{"id":61235,"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/posts\/61234\/revisions\/61235"}],"wp:attachment":[{"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/media?parent=61234"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/categories?post=61234"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/tags?post=61234"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\n
\n
\n
\n
\n
\n
\nRead More: FDA Announces It Will Not Issue Rules To Allow CBD As Dietary Supplements Or Food Items, Punting To Congress For Regulations<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"